DOUGLAS GINAS: Open Payments
NPI 1629059456 · ALBERTVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$993 in 55 payments from 17 companies in 2025. Trend: 2023 $732 · 2024 $759 · 2025 $993
Food & beverage: $993
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $255 |
| AstraZeneca Pharmaceuticals LP | 6 | $92 |
| Indivior Inc. | 3 | $88 |
| Novo Nordisk Inc | 5 | $87 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $79 |
| GlaxoSmithKline, LLC. | 3 | $63 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $61 |
| Braeburn Inc. | 2 | $52 |
| Exact Sciences Corporation | 2 | $37 |
| PFIZER INC. | 2 | $32 |
Products named: VRAYLAR, UBRELVY, SUBLOCADE, Ozempic, RELISTOR, TRELEGY ELLIPTA, Kerendia, BRIXADI.
Industry payments across AL — which companies pay providers there.
